MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer.
暂无分享,去创建一个
D. Neuberg | L. Chirieac | D. Christiani | R. Heist | J. Wain | T. Lynch | Wei Zhou | L. Su | Geoffrey Liu | T. Cogan-Drew | L. Su
[1] M. Spitz,et al. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. , 2006, Carcinogenesis.
[2] Y. Hirooka,et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Neuberg,et al. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. , 2006, Lung cancer.
[4] S. Zienolddiny,et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer , 2006, International journal of cancer.
[5] Wen Tan,et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer , 2006, Human mutation.
[6] D. Neuberg,et al. Vitamin D Is Associated with Improved Survival in Early-Stage Non–Small Cell Lung Cancer Patients , 2005, Cancer Epidemiology Biomarkers & Prevention.
[7] A. Levine,et al. A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells* , 2005, Journal of Biological Chemistry.
[8] Chih-Yi Chen,et al. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[10] L. Vassilev,et al. Targeting the p53–MDM2 interaction to treat cancer , 2004, British Journal of Cancer.
[11] R. Dziadziuszko,et al. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). , 2004, Lung cancer.
[12] Stephen N. Jones,et al. An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis* , 2004, Journal of Biological Chemistry.
[13] C. Cordon-Cardo,et al. MDM2 and prognosis. , 2004, Molecular cancer research : MCR.
[14] Guillermina Lozano,et al. MDM2, an introduction. , 2003, Molecular cancer research : MCR.
[15] M. Oren,et al. The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.
[16] C. Harris,et al. The p53 network in lung carcinogenesis , 2002, Oncogene.
[17] A. Levine,et al. The p53 functional circuit. , 2001, Journal of cell science.
[18] P. Hainaut,et al. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. , 2001, Carcinogenesis.
[19] Ya‐Wen Cheng,et al. MDM2 mRNA expression is a favorable prognostic factor in non‐small‐cell lung cancer , 2000, International journal of cancer.
[20] M. Tang,et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. , 2000, Journal of the National Cancer Institute.
[21] J. McLaughlin,et al. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[22] A. Levine,et al. Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. , 1999, Cancer research.
[23] S. Ishiguro,et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. , 1997, British Journal of Cancer.
[24] M. Tang,et al. Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.
[25] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[26] B. Ferris,et al. Epidemiology Standardization Project (American Thoracic Society). , 1978, The American review of respiratory disease.